Replies to post #10557 on Mast Therapeutics, Inc. (MSTX)

[pray]

All the pumping is worthless unless management shares positive updates. Very little right now, with new lows daily is not going to entice new shareholders. Add to that countless shareholders that have been burnt on all the pumps at $1.00, $2.00 and $3.00 and you can understand why there is so much skeptics.

Once ... And if I break even I am out of here. I tend to be drawn to stocks that value shareholders. Mstx could care less about theirs.

[jape1]

GOOD INFORMATION
Thanks for bringing us, really interesting stuff,

congratulations for your work

[Zevoman]

I'm in Long!! I took some INO profit off the table (had too- was up over 400%) and I have been looking for a position like this.

Thanks for your DD boost JB. Lots of good info here. I am having a hard time seeing much down-side to this one.... Plenty of cash, HUGE institutional ownership, Excellent pipeline profile and readout timeline, Analyst estimates averaging $1.50+, and an amazing entry point to boot. I’m in for 12K shares, and will be looking to avg down if it falls any further. Glad I found this one. This stock actually reminds me of INO when I bought in back in 2010. PPS was around the same levels, Company had just done a bit of reorganization, and there was huge upside potential. It took a while, but it finally jumped. I have a feeling we will see the same effect with MSTX as it holds many of the same Characteristics.

Good Luck All!

[flare9x]

MSTX - Seeing higher volume today

http://finance.yahoo.com/news/mast-therapeutics-reports-fourth-quarter-120000412.html

Key objectives for the remainder of 2013 include:
--Announcing results from the thorough QT/QTc study of MST-188, expected mid-year;
--Soliciting FDA input on our planned phase 2 study in acute limb ischemia, expected in the third quarter;
--Announcing results of nonclinical studies evaluating the physiologic significance of TEG results observed in prior nonclinical studies funded by the Defense Advanced Research Projects Agency (DARPA) Surviving Blood Loss (SBL) program, expected in the second half of the year;
--Initiating a microvascular blood flow sub-study in EPIC, expected in the fourth quarter;
--Initiating a phase 2 clinical proof-of-concept study of MST-188 in acute limb ischemia, expected in late 2013/early 2014;
--Obtaining orphan drug designation for MST-188 for acute limb ischemia;
--Submitting application(s) to request funding from the U.S. government to conduct a phase 2 clinical proof-of-concept study with MST-188 for resuscitation of shock following major trauma; and
--Filling patent applications claiming key aspects of our proprietary manufacturing process.

[pray]

And for the last 3 years they drop about half cent daily.

And you call that "excitement"

Close to now at all time low.

No one will touch this till CEO resigns or change in business strategy.

"Key Statistics

Key Statistics

52 week range: $.41-$.87
Outstanding Shares: 102.7 Million
Outstanding Shares: 102.7 Million"

Tomorrow will be new all time low and you can re post corrected.

Key Statistics

52 week range: $.40-$.87
Outstanding Shares: 102.7 Million

next day re-post
Key Statistics

52 week range: $.39-$.87
Outstanding Shares: 102.7 Million

next day re-post
Key Statistics

52 week range: $.38-$.87
Outstanding Shares: 102.7 Million

Yes ....EXCITING